Gut microbiota involved in bile acid biosynthesis, which influences NAFLD progression by regulating farnesoid X receptor (FXR) in the liver, and hepatic steatosis resulting from a high-fat diet (HFD), were reversed upon inhibition of intestinal FXR through alterations in the gut microbiota upon antibiotic administration [4, 5]. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.